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Abstract
Tumor necrosis factor (TNF)–related apoptosis-inducing
ligand (TRAIL) is cytotoxic to a wide variety of transformed
cells, but not to most normal cells, implying potential
therapeutic value against advanced cancer. However, signal
transduction in TRAIL-mediated apoptosis is not clearly
understood compared with other TNF family members.
Specifically, it is not yet understood how TRAIL controls
nuclear factor KB (NF-KB) activation and overcomes its
antiapoptotic effect. We explored the regulation of NF-KB
activity by TRAIL and its role in apoptosis. TRAIL combined
with IKBA-‘‘superrepressor’’ induced potent apoptosis of SK-
Hep1 hepatoma cells at low concentrations of TRAIL that
do not independently induce apoptosis. Apoptosis by high
concentrations of TRAIL was not affected by IKBA-super-
repressor. Although TRAIL alone did not induce NF-KB
activity, TRAIL combined with z-VAD significantly increased
NF-KB activation. Analysis of the NF-KB activation pathway
indicated that TRAIL unexpectedly induced cleavage of p65 at
Asp97, which was blocked by z-VAD, accounting for all of these
findings. p65 expression abrogated apoptosis and increased
NF-KB activity in TRAIL-treated cells. Cleavage-resistant
p65D97A further increased NF-KB activity in TRAIL-treated
cells, whereas the COOH-terminal p65 fragment acted as a
dominant-negative inhibitor. XIAP levels were increased by
TRAIL in combination with z-VAD, whereas XIAP levels were
decreased by TRAIL alone. Cleavage of p65 was also detected
after FRO thyroid cancer cells were treated with TRAIL. These
results suggest that TRAIL induces NF-KB activation, but
simultaneously abrogates NF-KB activation by cleaving p65,
and thereby inhibits the induction of antiapoptotic proteins
such as XIAP, which contributes to the strong apoptotic
activity of TRAIL compared with other TNF family members.
(Cancer Res 2005; 65(14): 6111-9)
Introduction
Members of the tumor necrosis factor (TNF) and TNF receptor
family play critical roles in the regulation of apoptosis,
inflammation, growth, and development. As a new member of
the TNF family, TNF-related apoptosis-inducing ligand (TRAIL)
has been reported to kill a wide variety of transformed cells,
including those resistant to other TNF family members (1, 2).
TRAIL does not kill most normal cells (1, 3) except certain
hematopoietic cells (4, 5), which suggest a potential therapeutic
role of TRAIL in the treatment of advanced cancer. However,
intracellular signal transduction in TRAIL-mediated apoptosis is
less clearly defined than are other TNF family members.
Activation of caspases (1, 6) and mitochondrial events are well
characterized (7–9). However, there has been controversy
regarding the roles of Fas-associated death domain protein and
nuclear factor nB (NF-nB) activation in TRAIL-induced apoptosis.
Several TNF family members, such as TNFa, induce NF-nB
activation that leads to inflammatory or antiapoptotic responses.
Candidates for NF-nB-inducible antiapoptotic genes include IAP
family members, FLIP, A1a, A20, and Gadd45h. Because of such
induction of antiapoptotic genes, TNFa itself does not induce
death in most cells. In contrast to TNFa, the physiologic function
of which is inflammation or protection of host organisms against
microbial infection, professional death effectors, such as Fas or
TRAIL, have been reported to induce minor or no activation of
NF-nB which might be related to more efficient death of target
cells. Whereas TRAIL has initially been reported not to activate
NF-nB (10, 11), a number of papers showed that TRAIL and its
authentic receptors, such as DR4 or DR5, activate NF-nB (11–13).
For TRAIL to have such a strong apoptotic activity on a variety of
cells, it would be expected that TRAIL should overcome the
antiapoptotic effect of NF-nB. However, it is far from clear how
TRAIL controls NF-nB activation and leads to the suppression of
its antiapoptotic effect.
In our study investigating NF-nB activation by TRAIL, we found
that caspases activated by TRAIL cleave p65, which leads to the
suppression of NF-nB activation and more efficient execution of
apoptosis. This could explain the strong apoptotic activity of
TRAIL compared with other TNF family members.
Materials and Methods
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay. Cells were seeded in 96-well microtiter plates (3  104 per well)
and treated with TRAIL (Calbiochem, La Jolla, CA) for the indicated time
periods at 250 ng/mL concentration unless otherwise indicated. In some
experiments, cells were pretreated with z-Val-Ala-Asp(Ome)-CH2F (z-VAD),
a pancaspase inhibitor (Enzyme Systems, Livermore, CA) for 30 minutes.
After TRAIL treatment, the medium was removed and 0.5 mg/mL 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added,
followed by incubation in a CO2 incubator at 37jC for 2 hours. After a brief
centrifugation, the supernatant was removed and DMSO was added. After
insoluble crystals were completely dissolved, absorbance at 540 nm was
read using a Thermomax microplate reader (Molecular Devices, Sunnyvale,
CA). In some experiments, cells were infected with adenovirus harboring
XIAP, p65, or InBa-superrepressor (kindly provided by Dr. Y. Lipp at the
University of Vienna, Vienna, Austria, Dr. C.D. Logsdon, University of
Michigan, MI, and Dr. C-T. Lee at Seoul National University Hospital, Seoul,
Korea, respectively) prior to treatment with TRAIL.
Measurement of caspase activity. Caspase-3-like activity was mea-
sured using a commercial caspase assay kit (PharMingen, La Jolla, CA)
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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according to the instructions of the supplier. In brief, caspase-3
fluorogenic substrates (Ac-DEVD-AMC) were incubated with cytokine-
treated cell lysate at 37jC for 1 hour. Liberated AMC was measured using
a fluorometric plate reader with an excitation wavelength of 380 nm and
an emission wavelength of 420 nm.
Electrophoretic mobility shift assay. Nuclear extracts were prepared
from SK-Hep1 cells treated with TRAIL for indicated times with or without
z-VAD pretreatment. Electrophoretic mobility shift assay was then done
using the nuclear extracts incubated with labeled probe containing
consensus NF-nB binding sequence (Promega, Madison, WI) as previously
described (14). For supershift assays, a total of 0.2 Ag of antibodies against
the p65 or p50 subunit of NF-nB (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) were included in the reaction.
Nuclear factor KB reporter assay. NF-nB reporter activity was
measured using the Dual-Luciferase Reporter Assay System (Promega).
In brief, cells in 24-well plates were cotransfected with 0.5 Ag of NF-nB-
responsive reporter gene construct carrying two copies of nB sequences
linked to luciferase gene (IgGn NF-nB-luciferase, generously provided by
Dr. G.D. Rosen, Stanford University, Stanford, CA) together with 0.01 Ag of
Renilla luciferase gene under herpes simplex virus thymidine kinase
promoter (pRL-TK, Promega) using LipofectAMINE reagent (Life Tech-
nologies, Gaithersburg, MD). At 24 hours after transfection, cells were
treated with TRAIL with or without z-VAD pretreatment. After an
additional 5 hours, activities of firefly luciferase and Renilla luciferase
were measured using the Dual-Luciferase Reporter Assay System. Results
were presented as firefly luciferase activity normalized to Renilla luciferase
activity. In some experiments, cells were cotransfected with 0.5 Ag of p65,
p65D97A, or Dp65 expression plasmid along with NF-nB-responsive
reporter plasmid (0.5 Ag) and pRL-TK (0.01 Ag).
Transient transfection of p65. After transfection of p65 or its
mutants, the number of apoptotic cells was counted as described (14). In
brief, SK-Hep1 cells in 24-well plates were cotransfected with 1 Ag of p65
(kindly provided by Dr. W.C. Greene, Duke University, Durham, NC),
p65D97A, or Dp65 expression plasmid together with 0.1 Ag of lacZ
(pCH110) using LipofectAMINE reagent. At 24 hours after transfection,
cells were treated with TRAIL. After another 24 hours, cells were fixed
with 0.5% glutaraldehyde for 10 minutes at room temperature and
stained with 1 mg/mL 5-bromo-4-chloro-3-indolyl-h-D-galactopyranoside
in 4 mmol/L potassium ferricyanide / 4 mmol/L potassium ferrocyanide
/ 2 mmol/L magnesium chloride at 37jC for the counting of blue cells.
Viable blue cells and dark blue apoptotic cells with rugged condensed
morphology in 10 random high-power fields (200) were counted. At
least 200 blue cells were counted for each experiment, and transfection
efficiency was 15% to 30%.
Western blot analysis. Cells were lysed in a buffer containing
50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% Triton X-100,
5 mmol/L EDTA, 0.5 mmol/L Na3VO4, 50 mmol/L NaF, 1 mmol/L
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Roche,
Mannheim, Germany). Protein concentration in cell lysate was determined
using a commercial protein assay kit (Bio-Rad, Hercules, CA). An equal
amount of protein for each sample was separated by 10% SDS-PAGE and
transferred to Hybond enhanced chemiluminescence membranes (Amer-
sham Pharmacia, Uppsala, Sweden). After incubation in a 1:1,000 dilution
of primary antibodies to phospho-IKKa/h, IKKh (Cell Signaling Technol-
ogy, Beverly, MA), InBa, p65, p50 (Santa Cruz), or XIAP (MBL, Nagoya,
Japan), membranes were probed with appropriate horseradish peroxidase-
conjugated secondary antibody (Amersham Pharmacia). Bound antibody
was visualized using an enhanced chemiluminescence reagent (Amersham
Pharmacia).
RT-PCR analysis. Total RNA was extracted using TRIzol Reagent (Life
Technologies). Reverse transcription was carried out using Superscript II
(Invitrogen, Carlsbad, CA) and oligo(dT)12-18 primer. PCR amplification
using primer sets specific for XIAP ( forward, GCAAGATGAGTCAAGTCA-
GACTTC; reverse, AGACATAAAAATTTTTTGCTTG) was carried out at
55jC annealing temperature for 25 cycles.
Site-directed mutagenesis. Point mutations (p65D97A and p65D449A)
were introduced to a prokaryotic p65 expression vector using the Quick
Change Mutagenesis Kit (Stratagene, La Jolla, CA). The oligonucleotides used
for in vitro mutagenesis were 5V-GAAAGGACTGCCGGGCTGGCTTCTAT-
TGAGGC-3V and 5V-AGTTTGATGATGAAGCCCTGGGGGCCTTGCTTGG-3V
for p65D97A and p65D449A, respectively. The mutant sequence was confirmed
by direct nucleotide sequencing.
In vitro cleavage of p65. In vitro translation of p65 and its mutants
(p65D97A and p65D449A) was carried out using a commercial kit (Promega)
according to the manufacturer’s protocol. In short, an amino acid mixture
without methionine, p65 DNA templates, S35-methionine, T7 RNA
polymerase, rabbit reticulocyte lysate, and RNase inhibitor was mixed in
a reaction buffer for incubation at 30jC for 90 minutes. After treatment of
SK-Hep1 cells with 250 ng/mL TRAIL, 0.5  106 cells were collected for each
sample, washed once with cold PBS, and resuspended in 50 AL of chilled
cell lysis buffer containing 10 mmol/L HEPES (pH 7.4), 50 mmol/L NaCl,
and 2 mmol/L MgCl2. Further cell lysis was done by freezing and thawing
for three to four cycles. After centrifugation at 14,000 rpm at a temperature
of 4jC for 15 minutes, 10 Ag of cell lysate was incubated for 1 hour at 37jC
with 5 AL of 35S-labeled wild-type or p65 mutants in a reaction buffer
containing 10 mmol/L HEPES (pH 7.4), 0.04% CHAPS, 4% glycerol, 0.4
mmol/L EDTA, and 2.5 mmol/L DTT. After boiling, samples were loaded
onto 10% SDS-PAGE gel.
Statistical analysis. All values were expressed as mean F SD (n = 3).
Student’s t test was employed to compare the means between the groups.
P values <0.05 were regarded as statistically significant.
Results
Caspase-sensitive nuclear factor KB activation by tumor
necrosis factor–related apoptosis-inducing ligand. Because the
role of NF-nB activation in TRAIL-induced apoptosis is not clearly
understood, we first studied whether the abrogation of NF-nB
activation by an InBa-superrepressor that is resistant to
degradation (15) could affect TRAIL-induced apoptosis. As
reported previously (8), TRAIL concentrations >250 ng/mL
induced significant apoptosis of SK-Hep1 hepatoma cells. In
contrast, TRAIL concentrations <100 ng/mL did not induce
notable death of SK-Hep1 cells. However, TRAIL concentrations
<100 ng/mL induced potent cell death when combined with
adenoviral expression of InBa-superrepressor, suggesting that NF-
nB activation occurs and affects SK-Hep1 cell death at low
concentrations of TRAIL. SK-Hep1 cell death induced by TRAIL
concentrations >250 ng/mL was not significantly enhanced by
InBa-superrepressor, suggesting that NF-nB activation observed
at lower concentrations of TRAIL is abrogated by higher
concentrations of TRAIL (Fig. 1A). SK-Hep1 cell death induced
by TRAIL concentrations >250 ng/mL showed classical apoptosis,
which is characterized by nuclear condensation, fragmentation,
sub-G1 peak on DNA ploidy assay (data not shown), and
induction of caspase-3-like activity as reported previously
(Fig. 1B ; ref. 8). z-VAD, a pancaspase inhibitor, completely blocked
caspase-3 activation and SK-Hep1 cell death induced by TRAIL
(Fig. 1B and C).
Because TRAIL concentrations >250 ng/mL seem to abrogate
NF-nB activation and lead to caspase activation, we next explored
the relationship between caspase activation and NF-nB activation.
Although TRAIL alone (250 ng/mL) did not induce NF-nB activity,
TRAIL in combination with z-VAD pretreatment induced
significant NF-nB activation (P < 0.05; Fig. 1D), suggesting that
activated caspases at high concentrations of TRAIL inhibit NF-nB
activation.
Cleavage of p65 by tumor necrosis factor–related apoptosis-
inducing ligand. To understand how NF-nB activation is
abrogated in apoptosis by high concentrations of TRAIL, we
Cancer Research
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tested whether z-VAD pretreatment affects TRAIL-mediated IKK
activation, InBa degradation, and NF-nB DNA binding activity
(Fig. 2). TRAIL induced a similar degree of IKKa/h phosphory-
lation and InBa degradation irrespective of z-VAD pretreatment
(Fig. 2A and B). The increase in IKKa/h phosphorylation was
paralleled by a decrease in InBa protein levels, which was
noticeable at 1 hour and peaked at 2 hours. Compared with
TNFa, the induction of IKK activity and the subsequent
degradation of InBa were relatively slow (Fig. 2C and D). We
then determined NF-nB DNA-binding activity by electrophoretic
mobility shift assay after TRAIL treatment with or without z-VAD
pretreatment. Remarkably, whereas TRAIL alone induced only
minor NF-nB DNA-binding activity, TRAIL in combination with z-
VAD pretreatment significantly enhanced NF-nB DNA-binding
activity (Fig. 2E), suggesting that TRAIL-mediated caspase
activation mainly affects NF-nB DNA-binding activity after a
similar degree of InBa degradation. In contrast, TNFa-induced
NF-nB activation was not affected by z-VAD pretreatment
(Supplementary Fig. S1), which is consistent with our observation
that TNFa induced no apoptosis of SK-Hep1 cells (data not
shown). Supershift analysis indicated that NF-nB complex
comprised both p50 and p65 subunits (data not shown). Thus,
we studied the potential changes to the p65/p50 NF-nB
components by TRAIL. Unexpectedly, immunoblot analysis
disclosed a band with a smaller molecular size (f55 kDa;
Dp65) which is recognized by anti-p65 antibody, indicating the
cleavage of p65 after TRAIL treatment. The cleavage of p65 was
blocked by z-VAD (Fig. 3A), suggesting that caspases activated by
TRAIL induce p65 cleavage and abrogate the NF-nB-dependent
antiapoptotic process as z-VAD enhances NF-nB activity after
TRAIL treatment (see Figs. 1D and 2). The cleaved p65 was
recognized by an antibody to the COOH terminus of p65, but not
by that to the NH2 terminus, which suggests that p65 is cleaved at
the NH2 terminus. No cleavage of p50 was detected during
TRAIL-induced apoptosis of SK-Hep1 cells (Fig. 3A). Because the
above results indicated in vivo cleavage of p65 in intact cells after
TRAIL treatment, we further investigated whether p65 could be
cleaved in vitro . In vitro translated p65 was, indeed, cleaved after
incubation with cell lysate prepared from TRAIL-treated cells
(Fig. 3B). The cleavage of p65 in vitro was abrogated by z-VAD,
suggesting that p65 cleavage is induced by activated caspases in
TRAIL-treated cells (Fig. 3B).
Figure 1. Increased NF-nB activity in TRAIL-treated cells by caspase inhibitors. A, SK-Hep1 hepatoma cells were infected with adenovirus [multiplicity of
infection (MOI), 50] harboring LacZ or InBa-superrepressor and treated with indicated concentrations of TRAIL. After 24 hours, viability was assessed using MTT assay.
z-VAD inhibited caspase-3-like activity (B ) and SK-Hep1 cell death (C ) by TRAIL. SK-Hep1 cells were left untreated or treated with TRAIL (250 ng/mL) for
6 hours (caspase activity assay) and 24 hours (viability assay) with or without z-VAD (50 Amol/L) pretreatment for 30 minutes, respectively. Caspase-3-like activity
was determined by AMC release using DEVD-AMC as a substrate. Viability was assessed as in (A). D, SK-Hep1 cells were cotransfected with 0.5 Ag of NF-nB
luciferase reporter construct together with 0.01 Ag of pRL-TK reporter construct. After 24 hours, transfected cells were left untreated or treated with TRAIL (250 ng/mL)
for 5 hours with or without z-VAD (50 Amol/L) pretreatment for 30 minutes. Relative firefly luciferase activities of NF-nB reporter normalized to Renilla luciferase
activities are shown.
p65 Cleavage by TRAIL
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To determine the cleavage site, we introduced point mutations
at previously reported putative caspase cleavage sites (16, 17).
When the mutant p65 protein harboring D97A substitution
(p65D97A) was translated in vitro and incubated with TRAIL-
treated cell lysate, no cleavage product was detected. Another
mutant harboring D449A substitution (p65D449A; ref. 17) was
cleaved like wild-type p65, indicating that Asp97, but not Asp449, is
the site preferentially cleaved in TRAIL-induced apoptosis. These
results are consistent with the recognition of the cleaved p65
fragment by the antibody to the COOH terminus but not by that
to the NH2 terminus (Fig. 3A). The results are also consistent with
the abrogated NF-nB DNA-binding activity in TRAIL-treated cells
because Asp97 is located in the DNA-binding domain of p65
(Fig. 2E).
Abrogation of tumor necrosis factor–related apoptosis-
inducing ligand–induced apoptosis by p65. Because these
results suggested that the cleavage of p65 by activated caspases
plays an important role in the execution of apoptosis by TRAIL,
we next studied whether p65 overexpression would reverse such
a process. Indeed, adenoviral p65 expression significantly
inhibited apoptosis of SK-Hep1 cells by TRAIL (Fig. 4A).
Additionally, we examined the effect of p65D97A, which is
resistant to the cleavage. Transfection of wild-type p65 reduced
apoptosis from 42% to 34%, and p65D97A transfection further
reduced apoptosis to 25%, which was significantly protective
compared with wild-type p65 (Fig. 4B , third versus fourth
column from the left; P < 0.05). The caspase-3-cleaved COOH-
terminal fragment of p65 (98-551; Dp65) did not inhibit cell
death. The expression of p65 also significantly increased NF-nB
reporter activity in TRAIL-treated cells (Fig. 4C ). TRAIL
significantly decreased NF-nB reporter activity by the expression
of p65 alone. This is probably due to activated caspases cleaving
both endogenous and exogenous p65 (Fig. 4C , third versus fourth
column from the left; P < 0.05). The expression of p65D97A
further increased NF-nB reporter activity in TRAIL-treated cells
compared with wild-type p65 expression in TRAIL-treated cells
Figure 2. Decreased NF-nB
DNA-binding activity by TRAIL-mediated
caspase activation. SK-Hep1 cells
were treated with TRAIL (250 ng/mL)
for indicated times with or without
z-VAD (50 Amol/L) pretreatment for
30 minutes. IKKa/h phosphorylation
(A ) and InBa degradation (B ) were
analyzed by Western blot analysis.
TRAIL-treated cells were pretreated
with ActD (0.1 Ag/mL) to prevent
resynthesis of InB, which might mask
InB degradation. SK-Hep1 cells were
treated with TNFa (10 ng/mL) for
indicated times, and IKKa/h
phosphorylation (C ) and InBa
degradation (D ) were analyzed by
Western blot analysis. E, NF-nB DNA
binding activity was analyzed by
electrophoretic mobility shift assay in
SK-Hep1 cells after treatment with
TRAIL (250 ng/mL) and/or z-VAD
pretreatment (50 Amol/L).
Cancer Research
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(Fig. 4C , fourth versus sixth column from the left; P < 0.05). The
expression of Dp65 did not increase NF-nB reporter activity
before or after TRAIL treatment (Fig. 4C). Furthermore, Dp65
inhibited NF-nB activation by wild-type p65 in a dose-dependent
manner, suggesting a dominant-negative role of Dp65 in NF-nB
activation (Fig. 4D). However, Dp65 transfection did not
significantly increase apoptosis after TRAIL treatment, likely
because of endogenously produced Dp65 (Fig. 4B , second versus
fifth column from the left; P > 0.1).
Degradation and synthesis of XIAP in apoptosis by tumor
necrosis factor–related apoptosis-inducing ligand. We next
studied whether TRAIL induced changes in the expression of
XIAP, an important NF-nB-inducible antiapoptotic molecule.
XIAP expression began to decrease from 6 hours after TRAIL
treatment and reached the nadir after 24 hours (Fig. 5A).
Adenoviral expression of XIAP almost completely inhibited
caspase-3-like activity and SK-Hep1 cell death induced by
TRAIL, suggesting that the disappearance of XIAP plays an
important role in the progression of the apoptotic process
induced by TRAIL (Fig. 5B). The disappearance of XIAP after
TRAIL treatment was abrogated by z-VAD, suggesting the
degradation of XIAP by activated caspases (Fig. 5A). Because
XIAP is a well-known target protein of NF-nB and because
activated caspase inhibited NF-nB activation after TRAIL
treatment, we further investigated the effect of caspase
activation on the production of XIAP. Although the potential
increase in the expression of XIAP protein by TRAIL/z-VAD was
not apparent, probably due to high basal levels of XIAP
(Fig. 5A), RT-PCR analysis showed that RNA levels of XIAP
were markedly increased by TRAIL/z-VAD but not by TRAIL
alone, suggesting that NF-nB activation by TRAIL plus caspase
inhibitors not only inhibited the degradation of XIAP by
activated caspases, but also increased XIAP synthesis, probably
through the activation of NF-nB (Fig. 5C).
Because high basal expression interfered with the study of
XIAP synthesis at the protein level, we studied the changes in
XIAP protein in a low-serum condition (1% fetal bovine serum)
where baseline expression was low (data not shown). As
hypothesized, an increase in XIAP protein levels after treatment
with TRAIL/z-VAD was clearly shown. TRAIL alone decreased
the XIAP protein level by activating caspases as expected
(Fig. 5D).
Cleavage of p65 in other cells. We finally studied whether
the cleavage of p65 in TRAIL-induced apoptosis is restricted to
SK-Hep1 cells or could be observed in other cells. All of the
three tested cells, including highly malignant FRO anaplastic
thyroid cancer cells, HeLa cells, and HEK293 cells, underwent
TRAIL-induced apoptosis, which was inhibited by z-VAD (Fig.
6A). In contrast, p65 cleavage was detected after TRAIL
treatment of FRO cells, but not after treatment of HeLa or
HEK293 cells (Fig. 6B). Whereas TRAIL alone did not induce NF-
nB activity in FRO cells, TRAIL in combination with z-VAD
induced a strong NF-nB activation, similar to that observed in
SK-Hep1 cells (Fig. 6C). TRAIL in combination with z-VAD
induced even stronger NF-nB activation in HeLa cells, suggesting
that the abrogation of NF-nB by activated caspases occurs
through pathways other than p65 cleavage, such as the cleavage
of RIP (18).
Discussion
Our results, which indicated that the expression of InBa-
superrepressor accelerated TRAIL-induced target cell death, are
similar to the results of previous reports (18, 19). However, the
effect of InBa-superrepressor was observed only when TRAIL
concentration was low and was not enough to independently kill
SK-Hep1 hepatoma cells. These results suggest that NF-nB is
activated by TRAIL, but the activation is abrogated by high
concentrations of TRAIL. Our results also suggested a reciprocal
relationship between NF-nB and caspase activation because the
latter was observed only at high concentrations of TRAIL,
whereas the effect of the former was manifest at both high and
Figure 3. Cleavage of p65 at Asp97 by TRAIL. A, SK-Hep1 cells were treated with TRAIL (250 ng/mL) for 2 hours with or without z-VAD (50 Amol/L) pretreatment for
30 minutes. Cell lysates were subjected to SDS-PAGE (10%), followed by Western blot analysis using specific antibodies to the COOH terminus and the NH2
terminus of p65 or p50. B, SK-Hep1 cells were treated with TRAIL (250 ng/mL) for 6 hours and cell lysates were prepared. Aliquots (5 AL) of in vitro translated [35S]
Met-p65 and mutants ([35S]Met-p65D97A or [35S]Met-p65D449A) were incubated with 10 Ag of cell lysate in the presence or absence of z-VAD (50 Amol/L) for
1 hour. Reaction mixtures were resolved on 10% SDS-PAGE, and autoradiography was obtained on the dried gel.
p65 Cleavage by TRAIL
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low concentrations of TRAIL. In our efforts to study the
relationship between NF-nB activation and caspase activation,
we observed that caspase inhibition by z-VAD enhanced NF-nB
activation, which is similar to a previous paper which showed an
increase in NF-nB activity by z-VAD in HeLa cells after TRAIL
treatment (18). In our effort to examine each component of the
NF-nB complex, we unexpectedly found that p65 was cleaved
during TRAIL-induced SK-Hep1 hepatoma cell apoptosis, which
seems to be responsible for the abrogation of NF-nB activation at
high TRAIL concentrations. The cleavage of p65 has been
reported in apoptosis by serum withdrawal, certain chemicals,
and Fas (16, 17, 20). However, p65 cleavage has not been shown in
other types of apoptosis, particularly apoptosis induced by TRAIL
and other TNF family members. The cleavage of p65 and
abrogation of NF-nB activation in TRAIL-induced apoptosis are
particularly interesting because TRAIL induces much stronger
apoptosis on a wider variety of cancer cells than do other types of
TNF family members, such as TNFa and Fas. p65 cleavage after
TRAIL treatment was not restricted to SK-Hep1 cells because
such cleavage was also noted after the treatment of FRO cells
with TRAIL. Active NF-nB components might be more accessible
to the cleavage by activated caspases than inactive NF-nB
components associated with InBa because the p65 cleavage
fragment after TRAIL treatment constituted a higher fraction of
the total p65 in nuclear extracts compared with cytosol extracts
(Supplementary Fig. S2). Other cells that do not show p65
cleavage after TRAIL treatment might have other ways of
abrogating NF-nB activation, such as the cleavage of RIP (18).
However, we cannot rule out the involvement of other
mechanism(s) for negating NF-nB activation after TRAIL treat-
ment in these cells, and further studies are required to determine
this possibility.
The cleavage site of p65 in TRAIL-induced apoptosis seemed
to be in the NH2-terminal DNA-binding domain because TRAIL
primarily decreased the NF-nB DNA-binding activity and the
cleaved p65 was recognized by an antibody to the COOH
terminus of p65, but not by an anti-NH2 terminus antibody. Our
in vitro translation study also showed that caspases activated by
TRAIL cleave the Asp-Cys-Arg-Asp97-Gly98 motif of p65 at the
DNA-binding domain (21), similar to a previous report employing
a menadione analogue as an apoptosis inducer (16). Consistent
with our hypothesis, transfection of a cleavage-resistant p65
Figure 4. Inhibition of TRAIL-induced apoptosis by p65 or its cleavage-resistant mutant. A, SK-Hep1 cells were infected with adenovirus (50 MOI) harboring p65
and treated with TRAIL (250 ng/mL). After 24 hours, viability was assessed using MTT assay. Inset, expression level of p65 after adenoviral transduction of p65
determined by Western blot analysis. B, SK-Hep1 cells were cotransfected with 1 Ag of p65, p65D97A, or Dp65 construct together with 0.1 Ag of lacZ construct. After
24 hours, transfected cells were left untreated or treated with TRAIL (250 ng/mL) for 24 hours and cells with apoptotic morphologic changes were counted in
lacZ-expressing cells. C, SK-Hep1 cells were cotransfected with expression plasmid encoding p65, p65D97A, or Dp65 (0.5 Ag each), together with NF-nB luciferase
construct (0.5 Ag) and pRL-TK construct (0.01 Ag). After 24 hours of transfection, cells were untreated or treated with TRAIL (250 ng/mL) for 5 hours and
luciferase reporter assay was done. D, SK-Hep1 cells were cotransfected with p65 (0.1 Ag), NF-nB luciferase construct (0.1 Ag), and pRL-TK construct (0.01 Ag)
together with increasing amounts of Dp65. Cells were harvested 24 hours after transfection, and luciferase reporter assay was done.
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mutant (p65D97A) inhibited apoptosis and increased NF-nB
reporter activity after TRAIL treatment further than that of
wild-type p65. The caspase-3-cleaved COOH-terminal fragment of
p65 (Dp65) that might be present in TRAIL-treated SK-Hep1 cells
could block the wild-type p65-induced NF-nB activation by
acting as a dominant-negative inhibitor. This may explain the
abrogation of NF-nB activation despite the persistent presence of
wild-type p65 together with the cleaved p65 in TRAIL-treated
cells.
In our effort to search for the target antiapoptotic proteins
that are induced by NF-nB in TRAIL-treated cells, we observed
that XIAP levels were markedly decreased after TRAIL treatment,
similar to previous reports (22, 23). The decrease in XIAP after
TRAIL treatment was completely reversed by caspase inhibitors,
which suggests that XIAP is degraded by activated caspases. The
decrease in XIAP level or XIAP degradation was not simply a
result of apoptosis but contributed to apoptosis because XIAP
overexpression abrogated caspase activation and SK-Hep1 cell
death by TRAIL. Activated caspases not only induced the
cleavage of XIAP, but also inhibited XIAP synthesis by cleaving
p65 and blocking NF-nB activation, which was shown by an
increase in XIAP RNA and protein levels after the treatment of
SK-Hep1 cells with TRAIL/z-VAD. These were not seen after
treatment with TRAIL alone.
At present, it is not clear whether caspase-mediated NF-nB
inactivation is a primary determinant in TRAIL-mediated
apoptosis and defects in this pathway contribute to inherent
TRAIL resistance or the development of resistance to TRAIL.
However, recent studies showed that sensitivity to TRAIL-
mediated apoptosis was reciprocally regulated by NF-nB
activation and was significantly enhanced by abrogating NF-nB
activation in some cancer cell lines (19, 24, 25), suggesting that
NF-nB is a key molecule underlying the TRAIL-resistant
mechanism. Furthermore, certain cancer cells were reported to
have either direct or indirect inactivating mutations of caspase
that might affect both the caspase-mediated NF-nB inactivation
and cellular apoptosis by TRAIL (26–28).
Taken together, these results indicate that p65 is cleaved by high
concentrations of TRAIL in some TRAIL-sensitive cells, leading to
the strong apoptotic activity of TRAIL compared with other TNF
family members. Dp65 that can form dimers but cannot bind to
specific DNA sequences, thus acting as a dominant-negative
inhibitor, could be used for sensitization of resistant cancer cells
to TRAIL or other TNF family members.
Figure 5. Induction of XIAP by TRAIL/z-VAD. A, SK-Hep1 cells were treated with TRAIL (250 ng/mL) for indicated times with or without z-VAD (50 Amol/L)
pretreatment for 30 minutes, and the XIAP protein level was analyzed by Western blot analysis. B, SK-Hep1 cells were infected with adenovirus (50 MOI) harboring
XIAP and treated with TRAIL (250 ng/mL) for 6 hours (caspase activity assay) and 24 hours (viability assay) with or without z-VAD (50 Amol/L) pretreatment for
30 minutes, respectively. Caspase-3-like activity was determined as in Fig. 1B and viability was assessed using MTT assay. Inset, expression level of XIAP after
adenoviral transduction of XIAP determined by Western blot analysis. C, SK-Hep1 cells were treated with TRAIL (250 ng/mL) for 6 hours with or without z-VAD
(50 Amol/L) pretreatment for 30 minutes. Cells were harvested for total RNA extraction and XIAP mRNA level was analyzed by RT-PCR. D, SK-Hep1 cells were cultured
in a low-serum condition (1% fetal bovine serum) for 24 hours. Cells were then treated with TRAIL (250 ng/mL) for 24 hours with or without z-VAD (50 Amol/L)
pretreatment for 30 minutes and the XIAP protein level was analyzed by Western blot analysis.
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Figure 6. p65 cleavage in other cells. A, FRO
thyroid cancer, HeLa cervical cancer, and
HEK293 cells were treated with TRAIL
(250 ng/mL) for 24 hours with or without z-VAD
(50 Amol/L) pretreatment for 30 minutes and
viability was assessed using MTT assay.
B, FRO, HeLa, and HEK293 cells were treated
with TRAIL (250 ng/mL) for 2 hours with or
without z-VAD (50 Amol/L) pretreatment
for 30 minutes. Cell lysates were subjected to
SDS-PAGE (10%), followed by Western blot
analysis using specific antibodies to the
COOH terminus and the NH2 terminus of p65.
C, FRO, HeLa, and HEK293 cells were
cotransfected with 0.5 Ag of NF-nB luciferase
reporter construct together with 0.01 Ag of
pRL-TK reporter construct. After 24 hours,
transfected cells were left untreated or treated
with TRAIL (250 ng/mL) for 5 hours and
luciferase reporter assay was done.
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